Humana (NYSE:HUM) PT Lowered to $360.00 at Cantor Fitzgerald

Humana (NYSE:HUM) had its price target trimmed by Cantor Fitzgerald from $391.00 to $360.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a neutral rating on the insurance provider’s stock. Cantor Fitzgerald also issued estimates for Humana’s FY2024 earnings at $16.04 EPS.

Several other research firms have also recently commented on HUM. TD Cowen lowered their target price on shares of Humana from $427.00 to $396.00 and set a buy rating for the company in a research note on Tuesday, April 2nd. Barclays reduced their target price on Humana from $356.00 to $310.00 and set an equal weight rating on the stock in a research report on Tuesday, April 2nd. The Goldman Sachs Group lowered their price target on Humana from $450.00 to $385.00 and set a buy rating for the company in a report on Wednesday, April 3rd. Argus lowered shares of Humana from a buy rating to a hold rating in a report on Wednesday, March 13th. Finally, Mizuho dropped their price target on shares of Humana from $550.00 to $400.00 and set a buy rating for the company in a research report on Friday, January 26th. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana presently has a consensus rating of Hold and a consensus target price of $424.50.

Humana Stock Performance

NYSE:HUM opened at $305.90 on Thursday. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. Humana has a twelve month low of $299.23 and a twelve month high of $541.21. The company has a market capitalization of $36.86 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 1.79 and a beta of 0.45. The firm has a 50-day moving average price of $327.77 and a two-hundred day moving average price of $393.91.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter last year, the business posted $9.38 EPS. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. As a group, research analysts expect that Humana will post 16.08 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.16%. Humana’s dividend payout ratio is currently 22.04%.

Insider Activity

In other news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the acquisition, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Mariner LLC increased its stake in shares of Humana by 2.3% in the third quarter. Mariner LLC now owns 14,119 shares of the insurance provider’s stock worth $6,869,000 after buying an additional 312 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Humana by 27.5% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 27,943 shares of the insurance provider’s stock worth $13,595,000 after purchasing an additional 6,034 shares during the last quarter. Silverarc Capital Management LLC acquired a new stake in shares of Humana in the 3rd quarter valued at about $4,865,000. Vest Financial LLC lifted its position in shares of Humana by 43.3% during the fourth quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider’s stock worth $12,815,000 after purchasing an additional 8,455 shares during the last quarter. Finally, Artemis Investment Management LLP grew its stake in Humana by 9.6% in the fourth quarter. Artemis Investment Management LLP now owns 64,573 shares of the insurance provider’s stock worth $29,563,000 after purchasing an additional 5,672 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.